Recent evidence suggests that mutant huntingtin protein-induced energetic perturbations contribute to neuronal dysfunction in Huntington's disease (HD). Given the ubiquitous expression of huntingtin, other cell types with high energetic burden may be at risk for HDrelated dysfunction. Early-onset cardiovascular disease is the second leading cause of death in HD patients; a direct role for mutant huntingtin in this phenomenon remains unevaluated. Here we tested the hypothesis that expression of mutant huntingtin is sufficient to induce cardiac dysfunction, using a well-described transgenic model of HD (line R6/2). R6/2 mice developed cardiac dysfunction by 8 weeks of age, progressing to severe failure at 12 weeks, assessed by echocardiography. Limited evidence of cardiac remodeling (e.g. hypertrophy, fibrosis, apoptosis, β 1 adrenergic receptor downregulation) was observed. Immunogold electron microscopy demonstrated significant elevations in nuclear and mitochondrial polyglutamine presence in the R6/2 myocyte. Significant alterations in mitochondrial ultrastructure were seen, consistent with metabolic stress. Increased cardiac lysine acetylation and protein nitration were observed and were each significantly associated with impairments in cardiac performance. These data demonstrate that mutant huntingtin expression has potent cardiotoxic effects; cardiac failure may be a significant complication of this important experimental model of HD. Investigation of the potential cardiotropic effects of mutant huntingtin in humans may be warranted.
Introduction
Huntington's disease (HD) is a devastating genetic disease, characterized primarily by a progressive loss of cognitive and motor function, leading to severe patient disability and death (Bates et al., 2002) . HD is caused by the mutation of a single ubiquitously expressed gene product of unknown function, the huntingtin protein, which contains an expanded polyglutamine repeat domain in HD patients (Huntington's Disease Collaborative Research Group, 1993) . The mechanisms by which mutant huntingtin causes cellular dysfunction and death remain undefined; recent evidence has implicated metabolic and energetic dysfunction in HD neurons (including mitochondrial effects) (Brennan et al., 1985; Browne et al., 1997; Koroshetz et al., 1997; Brouillet et al., 1999; SanchezPernaute et al., 1999; Schapira, 1999; Tabrizi et al., 1999; Ferrante et al., 2000; Jenkins et al., 2000; Tabrizi et al., 2000; Andreassen et al., 2001b; Panov et al., 2002; Panov et al., 2003; Choo et al., 2004; Brustovetsky et al., 2005; Milakovic and Johnson, 2005; Panov et al., 2005; Seong et al., 2005; Benchoua et al., 2006; Squitieri et al., 2006) . Biochemical and imaging studies in both HD patients and mouse models demonstrate reduced mitochondrial complex activities and altered metabolic substrate distributions (N-acetylaspartate, lactate, phosphocreatine) in the basal ganglia (Brennan et al., 1985; Browne et al., 1997; Sanchez-Pernaute et al., 1999; Schapira, 1999; Tabrizi et al., 1999; Jenkins et al., 2000; Schapiro et al., 2004; Jenkins et al., 2005; Reynolds et al., 2005; Tsang et al., 2006) . Despite increased food intake, HD patients can exhibit weight loss (Djousse et al., 2002; Hamilton et al., 2004; Trejo et al., 2004) and weight loss is a characteristic of transgenic mouse models of HD (Bates et al., 1998; Li et al., 2005; Stack et al., 2005) . Agents that boost mitochondrial efficiency (e.g. creatine, coenzyme Q) are under investigation as potential therapeutic strategies in HD patients (Koroshetz et al., 1997; Matthews et al., 1998; Ferrante et al., 2000; Huntington's Disease Study Group, 2001; Andreassen et al., 2001b; Schilling et al., 2001; Ferrante et al., 2002; Dedeoglu et al., 2003; Tabrizi et al., 2003; Verbessem et al., 2003; Ryu et al., 2005; Tabrizi et al., 2005; Hersch et al., 2006;  www.elsevier.com/locate/ynbdi Neurobiology of Disease 25 (2007) 297 -308 Abbreviations: HD, Huntington's disease; TUNEL, terminal deoxy nucleotidyl fragment end labeling; LV, left ventricle; FS, fractional shortening; LVID, LV internal dimension at diastole; VTI, velocity-time integrals; CO, cardiac output; β 1 -AR, β 1 -adrenergic receptor; 3NT, 3-nitrotyrosine; RNS, reactive nitrogen species.
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